More importantly, an approved orphan medicine in the EMA countries is expected to benefit from ten years of marketing exclusivity protection. An additional two years of exclusivity can be obtained if the drug-development has complied with an agreed pediatric investigation plan, with a total of twelve years of market exclusivity for a drug-that is approved for both adult and pediatric usage.


NNVC has previously reported that DengueCide was awarded orphan drug-status by the US FDA.


DengueCide is a nanoviricide(R) that has shown very high effectiveness in an animal model of dengue virus infection.